Herantis Pharma Plc
Company release, 18 June 2020 at 9:30 AM Eastern European Summer Time
An aggregate number of 39,600 new shares of Herantis Pharma Plc ("Herantis") have been subscribed for with option rights under the option programs 2010, 2014 and 2016 I. The new shares have been registered with the trade register maintained by the Finnish Patent and Registration Office today. The new shares will confer shareholder rights in Herantis after they have been issued in the book-entry system, on or about 19 June 2020.
Trading with the new shares is expected to commence on the Nasdaq First North Growth Market Finland marketplace on or about 22 June 2020, provided that Nasdaq Helsinki Ltd approves the listing application submitted by Herantis.
As a result of the share subscriptions, the total number of shares in Herantis will increase to 7,594,905.
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland with the ticker "HRTIS" and on Nasdaq First North Growth Market Sweden with the ticker "HRNTS". Subscribe to Herantis' news at https://herantis.com/subscribe/.